FDA-approved drug Epidiolex placed in schedule V of Controlled Substance Act
Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Nuestra historia
    • Divisiones Nacionales
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Recursos
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
      • Fee Waiver
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Recibir Actualizaciones
  • Scam Alert
  • Menú Completo
  • English
  • Español

Main Menu

Explore DEA
  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Nuestra historia
    • Divisiones Nacionales
    • DEA Museum
    • Wall of Honor
    • Contáctenos
  • Recursos
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas

Sobrescribir enlaces de ayuda a la navegación

  • Inicio
  • FDA-approved drug Epidiolex placed in schedule V of Controlled Substance Act

FDA-approved drug Epidiolex placed in schedule V of Controlled Substance Act

Septiembre 27, 2018
|
Share Article
|
Download Press Release
For Immediate Release
Contact: DEA Public Affairs
Phone Number: (202) 307-7977

WASHINGTON - The Department of Justice and Drug Enforcement Administration today announced that Epidiolex, the newly approved medication by the Food & Drug Administration, is being placed in schedule V of the Controlled Substances Act, the least restrictive schedule of the CSA.

In June 2018, the FDA announced it approved Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

Epidiolex contains cannabidiol (CBD), a chemical constituent of the cannabis plant (commonly referred to as marijuana).  The CBD in Epidiolex is extracted from the cannabis plant and is the first FDA-approved drug to contain a purified extract from the plant.

“DEA will continue to support sound and scientific research that promotes legitimate therapeutic uses for FDA-approved constituent components of cannabis, consistent with federal law,” said Acting DEA Administrator Uttam Dhillon.  “DEA is committed to continuing to work with our federal partners to seek ways to make the process for research more efficient and effective.”

“The FDA is committed to advancing scientific research and drug development programs that properly evaluate the active ingredients contained in marijuana,” said FDA Commissioner Scott Gottlieb, M.D. “Adequate and well-controlled clinical studies supported Epidiolex’s approval, so prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes. The FDA will continue to support rigorous scientific research on the potential medical uses of marijuana-derived products and stand ready to work with product developers who are interested in bringing patients safe and effective, high quality products.”

Marijuana and CBD derived from marijuana remain against the law, except for the limited circumstances that it has been determined there is a medically approved benefit. In those instances, such as here, the drug will be made appropriately available to the public for medical use. 

                                                                                                     # # #

Download Press Release
###
Marijuana (Cannabis)
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

@DEAHQ
  • Facebook
  • X
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Quienes Somos
    • Sobre
    • Contáctenos
    • Museo DEA
  • Recursos
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster